ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis

Michela Pasello1 · Anna Maria Giudice1,2,3 · Camilla Cristalli1 · Maria Cristina Manara1 · Caterina Mancarella1 · Alessandro Parra1 · Massimo Serra1 · Giovanna Magagnoli6 · Florencia Cidre-Aranaz5,6 · Thomas G. P. Grünewald5,6,7 · Carla Bini8 · Pier-Luigi Lollini3 · Alessandra Longhi9 · Davide Maria Donati10,11 · Katia Scotlandi1

Abstract

Purpose The relevance of the subfamily A members of ATP-binding cassette (ABCA) transporters as biomarkers of risk and response is emerging in different tumors, but their mechanisms of action have only been partially defined. In this work, we investigated their role in Ewing sarcoma (EWS), a pediatric cancer with unmet clinical issues.

Methods The expression of ABC members was evaluated by RT-qPCR in patients with localized EWS. The correlation with clinical outcome was established in different datasets using univariate and multivariate statistical methods. Functional studies were conducted in cell lines from patient-derived xenografts (PDXs) using gain- or loss-of-function approaches. The impact of intracellular cholesterol levels and cholesterol lowering drugs on malignant parameters was considered.

Results We found that ABCA6, which is usually poorly expressed in EWS, when upregulated became a prognostic factor of a favorable outcome in patients. Mechanistically, high expression of ABCA6 impaired cell migration and increased cell chemosensitivity by diminishing the intracellular levels of cholesterol and by constitutive IGF1R/AKT/mTOR expression/activation. Accordingly, while exposure of cells to exogenous cholesterol increased AKT/mTOR activation, the cholesterol lowering drug simvastatin inhibited IGF1R/AKT/mTOR signaling and prevented Ser166 phosphorylation of MDM2. This, in turn, favored p53 activation and enhanced pro-apoptotic effects of doxorubicin.

Conclusions Our study reveals that ABCA6 acts as tumor suppressor in EWS cells via cholesterol-mediated inhibition of IGF1R/AKT/MDM2 signaling, which promotes the pro-apoptotic effects of doxorubicin and reduces cell migration. Our findings also support a role of ABCA6 as biomarker of EWS progression and sustains its assessment for a more rational use of statins as adjuvant drugs.

Keywords Ewing sarcoma · ABC family of transporters · Cholesterol · Statins · Tumor biomarkers

1 Introduction

Mechanisms of chemoresistance in cancer are manifold and only partially defined. They include, but are not limited to, enhanced drug efflux-pump activity, changes in the intracellular metabolic machinery, upregulation of DNA repair mechanisms, induction of growth signaling and impairment of apoptosis [1]. Recent evidence indicates a more complex role for several ATP-binding cassette (ABC) transporters in tumor progression. Some ABC transporter members, particularly ABCB1 (P-glycoprotein/MDR1), ABCC1 (Multidrug Resistance-associated Protein 1/MDR1) and ABCG2 (Breast Cancer Resistance Protein/BCRP) act as cell membrane pumps that are capable of extruding drugs from cancer cells, and their contribution to multidrug resistance is widely recognized in different tumors (for a review, see [2]). Other members have been found to play roles in the regulation of cancer cell proliferation, differentiation, migration and invasion, to mediate intracellular peptide and lipid transport (for a review, see [3, 4]) and to be part of the signaling networks that orchestrate the activation and polarization of macrophages and to affect
the fate of myeloid progenitors [5, 6]. In this study, we focus on studying the impact of unconventional ABC transporters in Ewing sarcoma (EWS) and we use patient-derived xenograft (PDX) models to identify mechanisms of action for the ABCA6 transporter that has emerged as a prognostic biomarker in EWS patients.

The ABCA subfamily of transporters consists of 12 members, whose best-defined physiological functions are related to the maintenance of lipid homeostasis and the regulation of cellular lipid transport and trafficking, including efflux from cells of cholesterol and phospholipids (i.e., phosphatidylcholine, phosphatidylserine and sphingomyelin) (for a review, see [7]). These lipids are reported to severely impact many biological processes related to cancer by regulating plasma membrane cell fluidity and functionality (for a review, see [8, 9]), but information on this subfamily of transporters in cancer is dispersed, controversial and mostly limited to the ABCA1 member [8, 10]. In our current study, we found that high tumor levels of ABCA6 were predictive of a favorable prognosis in EWS patients. We chose to study EWS, the second most frequent primary tumor of bone in the pediatric population because (i) patients still face the disadvantage of uniform, non-individualized chemotherapy, which severely impacts their quality of life and/or prognosis [11], (ii) patients who fail to respond to first-line treatments or already had metastases at diagnosis still have a dismal prognosis (overall survival rate <40%), largely because their tumors are resistant to conventional chemotherapy [12, 13] and (iii) data for ABCB1, ABCG2 and ABCC1 are scarce and controversial in EWS [14–17], supporting the need of extended analysis and evaluation of novel candidates.

Our findings highlight the importance of ABCA6 as a biomarker of risk and response in EWS and provide a mechanistic explanation for its involvement in the regulation of cancer aggressiveness. High expression of this transporter impaired cell migration and increased cell chemosensitivity to DNA-damaging agents by diminishing intracellular cholesterol content, thereby decreasing the functional activity of the IGF1R/AKT/mTOR/MDM2 axis. The cholesterol-lowering drug simvastatin recapitulated similar effects and exhibited synergistic anti-proliferative and pro-apoptotic effects when combined with doxorubicin. This effect was particularly relevant in the most aggressive cells characterized by a low expression of ABCA6 and a high intracellular level of cholesterol.

2 Materials and methods

2.1 Patients selection

Patients with localized EWS who were enrolled in prospective neoadjuvant studies [18, 19] and treated at the Rizzoli Institute were included in this analysis. Based on biobank availability and a tumor tissue quality control check, 103 primary tumors were studied (25 samples: training set and 78 samples: validation set). The clinicopathological features of the patients are reported in Supplementary Table 1. Local treatment, performed after induction chemotherapy, consisted of radiation therapy, surgery or surgery followed by radiation therapy. In patients locally treated by surgery, the histological response to chemotherapy was evaluated according to the method proposed by Picci et al. [20].

For the training set, the median follow-up was 72 months (range 10–328 months). The cohort was composed of 9 patients (36%) who remained continuously free of disease (NED) and 16 patients (64%) who relapsed (REL). For the validation set, the median follow-up was 61.5 months (range 4–328 months), 44 patients (56.4%) remained continuously free of disease, and 34 (43.6%) relapsed. Clinical and follow-up data were updated to June 2020. Relapse-free survival (RFS) was calculated from the date of initial diagnosis. The clinical endpoint was the occurrence of adverse events (defined as recurrence or metastases at any site for RFS or cancer-related death for overall survival, OS).

Additionally, microarray data of 166 primary EWS tumors downloaded from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) were analyzed. More details are provided in the Supplementary Methods.

2.2 Preclinical studies

Functional studies were conducted on 4 cell lines derived from patient-derived xenografts (PDXs). PDX-derived cell lines, named PDX-EW#2-C, PDX-EW#3-C, PDX-EW#4-C and PDX-EW#5-C, were obtained from the respective EWS PDXs after their first passage in mice [21]. All cell lines were immediately amplified to construct liquid nitrogen stocks and were never passaged for more than 1 month upon thawing. Cells were maintained in Iscove’s modified Dulbecco’s medium (IMDM; Euroclone) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Euroclone), penicillin (20 U/ml) and streptomycin (100 μg/ml; Sigma) in a 37 °C humidified environment at 5% CO₂. All cell lines were authenticated by short tandem repeat PCR analysis (17 STRs analyzed; last control July 2018; POWERPLEX ESX 17 Fast System, Promega) and found to be mycoplasma-free using a MycoAlert mycoplasma detection kit (Lonza; control every 3 months).

For forced expression or silencing of ABCA6, 1 × 10⁶ PDX-EW#2-C or PDX-EW#5-C cells/well, respectively, were seeded in 6-well plates coated with fibronectin (3 μg/cm²; Sigma). For forced expression, cells were transfected 24 h after seeding with expression vector pCMV6-AC-GFP containing full-length hABCA6 (Origene), and
non-transfected (NT) or empty vector transfected (EV) cells were used as controls. For silencing, cells were transfected with a lentiviral pLKO.1 expression vector containing short hairpin RNAs (shRNAs) against human ABCA6 (shABCA6). Five constructs were mixed to ensure adequate coverage of the target gene (sequences 5'-3' of shRNA were as follows: shABCA6-1 ATTCCGTCTGTTAATTCTGC, shABCA6-2 TTTAAGTAAAGACCGAGG, shABCA6-3 AATAAGGGAGAATATGCCC, shABCA6-4 TAGCAAGTGCTG AAAATGGGG, shABCA6-5 TTTACCAGAAAACATATGG TACCG; human TRC shRNA library TRC-Hs1.0 Human; Dharmacon). Non-transfected (NT) cells or cells transfected with a pLKO.1 expression vector containing shRNA against enhanced green fluorescent protein (shGFP) were used as controls. Transfections were performed using TransIT-X2 (Mirus) according to the manufacturer’s protocols. The expression levels of ABCA6 were determined by western blot analysis after 48 h of transfection.

Anchorage-independent growth was determined in 0.33% agarose (Lonza) with a 0.5% agarose underlay. Cell motility and chemotaxis assays were performed using Transwell chambers (Costar) and scratch wound-healing assays. In vitro drug sensitivity was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (TACS MTT Cell Proliferation Assays; Trevigen) according to the manufacturer’s protocol or by Trypan blue vital cell count (Sigma). Changes in mitochondrial membrane potential were assessed by flow cytometry measuring 1,1'-3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1; Sigma) red and green fluorescence intensities. Intracellular cholesterol was detected using filipin III staining. Intracellular and supernatant cholesterol was quantified using a colorimetric Total Cholesterol Assay Kit (Cell Biolabs). Lipid extracts were obtained from 1×10^6 cells using 200 μl of a chloroform/isopropanol: NP-40 (7:11:0.1, v:v:v) mixture and further processed according to the manufacturers’ protocol.

For western blot analysis, cells were lysed with phospho-protein extraction buffer supplemented with protease-phosphatase cocktail inhibitor (Sigma). Proteins of interest were detected by specific antibodies.

More details on the preclinical studies are provided in the Supplementary Methods.

### 2.3 Statistical analysis

Associations between ABC transporter expression and RFS or OS were estimated by Cox proportional hazards regression analysis. RFS and OS were plotted using the Kaplan–Meier method, while the log-rank test was used to calculate univariate statistical significance of observed differences. Survivors or patients who were lost at follow-up were censored at the last contact date. All factors significantly associated with RFS in univariate analysis were entered into a Cox proportional hazards model multivariate analysis. Values of 95% confidence intervals (CIs) of hazard ratios (HRs) were provided [22]. All experiments were performed at least in triplicate, and all values are reported as the mean ± SEM. Differences among means were analyzed using unpaired two-sided Student’s t-test. Experimental data including more than 2 groups were analyzed using one-way or two-way ANOVA. Fisher’s exact test was used for association data. IC50 values were calculated from linear transformation of dose–response curves using CalcuSyn software (Biosoft). To define drug-drug interactions, the combination index (CI) was calculated with an isobologram equation using CalcuSyn software to identify synergistic (CI < 0.9), additive (0.9 ≤ CI ≤ 1.1), or antagonistic (CI > 1.1) effects according to Chou et al. [23]. All p values were two-sided and a p value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software, version 22.0 and GraphPad Prism 6 (GraphPad Prism).

### 3 Results

#### 3.1 High expression of ABCA6 in primary tumors predicts favorable outcomes in EWS patients

To identify ABC transporters whose expression is associated with differential patient outcome in EWS, we performed an explorative quantitative reverse transcription PCR (RT-qPCR) analysis of 15 ABC transporters that were reported to play a role in drug resistance/tumor aggressiveness (for a review see [24]). The median value for each gene (Supplementary Table 2) was used as the cutoff value to stratify patients and define two categories of high or low expressers.

In the training set (25 samples from patients with primary localized EWS), the log-rank univariate analysis (Mantel-Cox test) indicated a statistically significant association for the expression of ABCA6 and ABCA7 with different RFS (Table 1 and Supplementary Fig. 1). However, this correlation was confirmed only for ABCA6 in the validation set (78 samples from patients with primary localized EWS): high expression of ABCA6 was found to be associated with favorable patient’s outcomes, using RFS and OS as a primary endpoint (Fig. 1a, Supplementary Table 3 and Supplementary Table 4). In patients with high expression of ABCA6, adverse events occurred in 10 out of 34 (29.4%), while in patients with low expression of ABCA6 adverse events occurred in 24 out of 34 (70.6%) (p = 0.003, Fisher’s exact test). Accordingly, tumor-related death occurred in 30.4% (7 out of 23) of patients with high expression of ABCA6, but in 69.6% (16 out of 23) of patients with low expression of the transporter (p = 0.046, Fisher’s exact test). Multivariate analysis supported the statistical significance of the low expression level of ABCA6 as an independent risk factor for poor outcomes.
Table 1 Prognostic impact of ABC transporters in 25 patients with Ewing sarcoma. Associations with prognosis were calculated by univariate analysis using the log-rank (Mantel-Cox) test.

| Gene   | n  | Events (% RFS) | p-Univariate | Events (% OS) | p-Univariate |
|--------|----|----------------|--------------|---------------|--------------|
| ABCA2  | 13 | 10 (17.9%)     | 0.067        | 8 (34.6%)     | 0.103        |
|       | 12 | 6 (50.0%)      |              | 4 (66.7%)     |              |
| ABCA6  | 12 | 9 (20.8%)      | 0.026        | 7 (38.1%)     | 0.085        |
|       | 13 | 7 (46.2%)      |              | 5 (61.5%)     |              |
| ABCA7  | 13 | 11 (8.8%)      | 0.035        | 9 (26.0%)     | 0.023        |
|       | 12 | 5 (58.3%)      |              | 3 (75.0%)     |              |
| ABCB1  | 12 | 8 (29.2%)      | 0.530        | 7 (37.5%)     | 0.215        |
|       | 13 | 8 (38.5%)      |              | 5 (61.5%)     |              |
| ABCB10 | 12 | 8 (28.1%)      | 0.951        | 5 (55.6%)     | 0.563        |
|       | 13 | 8 (38.5%)      |              | 7 (46.2%)     |              |
| ABCC1  | 12 | 9 (18.7%)      | 0.468        | 6 (46.3%)     | 0.965        |
|       | 13 | 7 (46.2%)      |              | 6 (53.8%)     |              |
| ABCC2  | 12 | 8 (28.1%)      | 0.967        | 6 (46.3%)     | 0.859        |
|       | 13 | 8 (38.5%)      |              | 6 (53.8%)     |              |
| ABCC4  | 12 | 10 (9.7%)      | 0.055        | 8 (28.1%)     | 0.055        |
|       | 13 | 6 (53.8%)      |              | 4 (69.2%)     |              |
| ABCC5  | 12 | 10 (9.5%)      | 0.080        | 7 (37.5%)     | 0.361        |
|       | 13 | 6 (53.8%)      |              | 5 (61.5%)     |              |
| ABCC11 | 12 | 6 (46.9%)      | 0.172        | 5 (55.6%)     | 0.535        |
|       | 13 | 6 (23.1%)      |              | 7 (46.2%)     |              |
| ABCE1  | 13 | 10 (17.6%)     | 0.142        | 7 (42.7%)     | 0.446        |
|       | 12 | 6 (50.0%)      |              | 5 (58.3%)     |              |
| ABCF1  | 12 | 10 (9.5%)      | 0.065        | 7 (37.5%)     | 0.348        |
|       | 13 | 6 (53.8%)      |              | 5 (61.5%)     |              |
| ABCF2  | 12 | 9 (19.0%)      | 0.329        | 6 (46.3%)     | 0.837        |
|       | 13 | 7 (46.2%)      |              | 6 (53.8%)     |              |
| ABCF3  | 12 | 9 (19.4%)      | 0.123        | 7 (38.1%)     | 0.212        |
|       | 13 | 7 (46.2%)      |              | 5 (61.5%)     |              |
| ABCG2  | 12 | 8 (30.0%)      | 0.284        | 6 (47.6%)     | 0.498        |
|       | 13 | 8 (38.5%)      |              | 6 (53.8%)     |              |

Results in bold are significant at \( p < 0.05 \). \(^a\)RFS, relapse-free survival (median follow-up: 21 months; range 4–328 months); \(^b\)OS, overall survival (median follow-up: 72 months; range 10–328 months)
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the...

(HR = 2.812; 95% CI = 1.226–6.445; p = 0.015) (Supplementary Table 5).

To validate the data obtained from our clinical samples and to limit the impact of possible technical biases, gene expression data obtained from publicly available microarray records of 166 primary EWS tumors were analyzed. The 22nd percentile, which indicates a low expression of the molecule, was chosen as the optimal cutoff by a specific algorithm, which tests all possible cutoffs between the 20th and 80th percentile of the entire range of all gene expression values for the given gene in the given dataset. The analysis still confirmed the significant association between high expression of ABCA6 and a better prognosis (Fig. 1b), further supporting the idea that ABCA6 could contribute to determine the outcome for EWS patients. Additionally, publicly available data showed that ABCA6 was expressed at lower levels in EWS compared with other pediatric tumors, particularly lymphoma/leukemia (Fig. 1c), suggesting the lack of this transporter as a peculiar feature of EWS.

Fig. 1 Prognostic value of ABCA6 in primary EWS patients. a, Prognostic impact of ABCA6 expression according to Kaplan–Meier curves and log-rank test in 78 EWS cases analyzed by RT-qPCR. Samples with high (H) and low (L) expression were defined according to the median value. Relapse-free survival (RFS) and overall survival (OS) were evaluated. The time scale refers to months from diagnosis. The number of patients at risk in the H and L groups is listed below each time interval. b, Kaplan–Meier analysis of OS of EWS patients (n = 166), stratified in two groups according to their ABCA6 expression status in ‘high’ and ‘low’ (cut-off 22nd expression percentile). All EWS tumors were profiled on Affymetrix gene expression arrays. Mantel–Haenszel test. c, Comparative gene expression analysis of ABCA6 in EWS (grey color; n = 50) and other solid and hematologic (pediatric) cancers (n ≥ 20 per canter type). Gene expression data were generated on Affymetrix HG-U133Plus2.0 arrays, downloaded from public repositories, manually curated and jointly normalized using RMA and brainarray CDF. Data are displayed as box-plots: the horizontal bars represent median expression values, boxes the interquartile range, and whiskers the 10th–90th expression percentile. CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; R-ARMS pos, alveolar rhabdomyosarcoma fusion-positive; R-ARMS neg, alveolar rhabdomyosarcoma fusion-negative; pediatric AML, pediatric acute myeloid leukemia.
3.2 ABCA6 levels influence EWS cell migration and chemosensitivity by affecting intracellular cholesterol content

Since the expression levels of ABCA6 in PDXs and in the corresponding PDX-derived cell lines were found to be more similar to those found in clinical samples than in conventional cell lines with a long history in culture (Supplementary Fig. 2), we decided to use the PDX-derived cell lines to study in more detail the impact that this transporter has on the regulation of tumor cell growth and migration. Among the four PDX-derived cell lines, PDX-EW#2-C cells barely expressed the transporter and PDX-EW#4-C cells showed a low expression, while PDX-EW#3-C and PDX-EW#5-C expressed ABCA6 at high levels (Fig. 2a).

In keeping with clinical data, the two cell lines with a high expression of ABCA6 displayed decreased capabilities to grow in anchorage-independent conditions and to migrate (Fig. 2b and c). Due to the severe limitations on cell growth and migration that characterize the PDX-EWS#3-C cells, we decided to perform further studies on the PDX-EWS#5-C cell line that still represents the high ABCA6 condition. We found that PDX-EW#5-C cells (ABCA6 high) exhibited a significantly enhanced sensitivity to DNA damaging chemotherapeutics doxorubicin \((p = 0.003, \text{Student’s t-test})\), etoposide \((p = 0.004, \text{Student’s t-test})\) and ifosfamide \((p = 0.028, \text{Student’s t-test})\) compared to PDX-EW#2-C cells (ABCA6 low) (Supplementary Table 6). The exposure of cells to doxorubicin induced a dose-dependent increase in mitochondrial depolarization, which was significantly higher in PDX-EW#5-C cells (ABCA6 high) than in PDX-EW#2-C cells (ABCA6 low) \((p < 0.0001, \text{two-way ANOVA}; \text{Fig. 2d})\), leading to increased activation of caspase-3 and PARP cleavage (Fig. 2e). Gain- or loss-of-function approaches in PDX-EW#2-C cells (ABCA6 low) (Fig. 3, left panel) or PDX-EW#5-C cells (ABCA6 high), respectively (Fig. 3, right panel), confirmed that the migration of EWS cells was indeed impaired when the transporter was overexpressed (Fig. 3b, left panel) and promoted when it was silenced (Fig. 3b, right panel). Overexpression of ABCA6 also enhanced cell chemosensitivity to doxorubicin (Fig. 3c, left panel) by improving its pro-apoptotic effects (Fig. 3d, left panel), while the abrogation of its expression led to opposite results (Fig. 3c and d, right panel).

Members of the ABCA subfamily of transporters are thought to play important roles in lipid transport and trafficking, including the regulation of cholesterol efflux from cells (for a review, see [3]). Thus, both cholesterol intracellular levels and the amount released into the culture medium were measured in PDX-derived EWS cells with differential expression levels of ABCA6. We observed reduced intracellular levels of cholesterol and higher cholesterol contents in the medium of the less aggressive PDX-EWS#5-C cells (ABCA6 high) compared to PDX-EWS#2-C cells (ABCA6 low) (Fig. 4a). Consistently, decreased or enhanced cholesterol levels were measured in ABCA6-overexpressing or -silenced cells, respectively, compared to non-transfected controls (NT, Fig. 4a). Staining of cells with filipin III, a fluorescent dye that specifically stains membrane-bound cholesterol [25], confirmed the reduced intracellular levels of cholesterol in the less aggressive PDX-EWS#5-C cells (ABCA6 high; Supplementary Fig. 3). In contrast, in the PDX-EWS#2-C cells (ABCA6 low), cholesterol was well detectable at the cell surface membrane and at the intracellular level (Supplementary Fig. 3). Functional relationships between ABCA6 expression, intracellular levels of cholesterol and malignant features of EWS cells were confirmed by exposing cells to simvastatin, a well-known inhibitor of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) in the cholesterol synthesis pathway [26], or exogenous cholesterol. In cells characterized by low expression of ABCA6 and high intracellular levels of cholesterol (PDX-EWS#2-C or PDX-EWS#5-C cells silenced), treatment with simvastatin diminished the cellular content of cholesterol, as expected, and weakened the migration abilities of cells in a dose-dependent manner (Fig. 4b and c). In contrast, the exposure of cells characterized by high expression of ABCA6 and low intracellular levels of cholesterol (PDX-EWS#5-C cells or PDX-EWS#2-C cells forced for ABCA6 expression) to exogenous cholesterol increased the intracellular levels of the lipid and induced a dose-dependent enhancement of migrated cells (Fig. 4d and e). As further confirmation, the inhibitory effect of simvastatin on ABCA6 low cell migration was completely reversed by exogenous cholesterol (Supplementary Fig. 4).

In PDX-EWS#2-C cells, pretreatment with simvastatin also increased the sensitivity to doxorubicin in the most aggressive ABCA6 low cells. Indeed, a clear synergistic effect between the two drugs was observed in ABCA6 low cells, but not in the less aggressive ABCA6 high cells (Fig. 5a). Additionally, while the silencing of ABCA6 expression in PDX-EW#5-C (ABCA6 high) cells induced synergism (Fig. 5b right), the forced expression of ABCA6 in PDX-EW#2-C (ABCA6 low) cells partly reversed the favoring effect of simvastatin (Fig. 5c right). This implies that cholesterol lowering drugs should be especially considered for the treatment of the most aggressive cells characterized by low expression of the transporter. Accordingly, the PDX-EW#2-C (ABCA6 low) cells were found to be more sensitive to simvastatin than the PDX-EW#5-C (ABCA6 high) cells (IC50 values \(= 63.65 \pm 5.47 \mu g/ml \) vs \(188.99 \pm 16.82 \mu g/ml\), respectively; \(p = 0.0021, \text{Student’s t-test})\).
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the...

3.3 ABCA6-mediated variations in intracellular levels of cholesterol impair activation of IGF1R/AKT/mTOR signaling while promoting doxorubicin-induced apoptosis

To illustrate the mechanisms that connect the expression of ABCA6 and the levels of cholesterol to cell migration and drug resistance, we treated the most aggressive PDX-EWS#2-C cells (ABCA6-low) with simvastatin, while the less aggressive PDX-EWS#5-C (ABCA6-high) and PDX-EWS#4-C (ABCA6-high) cells were exposed to exogenous cholesterol. Previous studies have shown that cholesterol-lowering drugs could inhibit AKT signaling in cancer cells by downregulating IGF1R expression [27, 28]. In our experimental model, we found that (i) transient overexpression or silencing of ABCA6 modulated AKT phosphorylation (Supplementary Fig. 5) and (ii) incubation of PDX-EWS#2-C cells with simvastatin (1–5 μg/ml) decreased the constitutive level of AKT phosphorylation on residue Ser473 (Fig. 6a). The effect lasted at least 72 h and was associated with upstream lower expression and phosphorylation on residue Tyr1131 of IGF1R, a key participant in EWS development and progression [29] and reduced
M. Pasello et al.

Fig. 3 Forced expression or silencing of ABCA6 affects cell migration and chemosensitivity to doxorubicin. a, Expression of ABCA6 in PDX-EW#2-C cells after forced expression (left) or in PDX-EW#5-C cells after silencing (right) determined by western blotting. A representative experiment of three is shown. GAPDH was used as a loading control. b, Migratory ability of PDX-EW#2-C and PDX-EW#5-C transfected cells. Data are the mean±SEM (n = 3); *p < 0.05, **p < 0.01, one–way ANOVA vs control (non-transfected cells; NT). c, Sensitivity to doxorubicin (DXR) of transfected cells, expressed as IC50 values, after 24 h of treatment. Data are the mean±SEM (n = 3); **p < 0.01 one–way ANOVA vs control (non-transfected cells; NT). d, Mitochondrial depolarization after cells exposure to DXR (24 h) detected by flow cytometry. Sensitivity to DXR of control cells was compared to that of ABCA6 overexpressing (hABCA6) or ABCA6 silenced cells (shABCA6). Data are the mean±SEM (n = 3). ***p < 0.001, two-way ANOVA.

downstream phosphorylation of mTOR on residue Ser2448 and ribosomal protein S6 on residue Ser240/244 (Fig. 6a). The simvastatin-induced IGF1R/AKT/mTOR inhibition in PDX-EWS#2-C cells was reversed by exogenous cholesterol (Fig. 6a). Accordingly, exposure of PDX-EWS#5-C (ABCA6high) cells to cholesterol stimulated phosphorylation of IGF1R and downstream mediators (Fig. 6b). Previous studies [30–32] have shown that cholesterol modification disrupts lipid raft domains, including caveolae [33] and alters the interaction among lipid raft-associated proteins. We here confirmed that overexpression of ABCA6 in PDX-EWS#2-C cells or their exposure to simvastatin led to decreased expression of caveolin-1, while ABCA6 silencing in PDX-EWS#5-C cells or their exposure to exogenous cholesterol led to increased levels of caveolin-1 on the cell surface (Supplementary Fig. 6). Although it is beyond the purpose of this study, a deeper evaluation of the cholesterol-caveolin-IGF1R signaling interactions, IGF1R being
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the...

ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the...

1 3

a resident of lipid rafts and caveolae [30, 31], it is very likely that cholesterol depletion followed by ABCA6 high expression could inhibit IGF1R and AKT signaling. This implies that the higher content of cholesterol, which characterizes EWS cells with low expression of the ABCA6 transporter, favors the constitutive IGF1R/AKT/mTOR signaling activation that is known to be sustained by the autocrine production of IGF1 [34, 35]. Accordingly, a comparison between untreated PDX-EWS#2-C and PDX-EWS#5-C cells clearly showed the highest constitutive signaling activation in the cell line with a lower expression of ABCA6, a higher content of cholesterol and a more aggressive phenotype (Fig. 6a and b). In PDX-EW#2-C cells, simvastatin, besides hampering AKT signaling also reduced Ser 166 phosphorylation of MDM2 (Fig. 6c), leading to increased p53 activation [36]. The effects on MDM2/p53 were further increased when simvastatin-pretreated cells were exposed to doxorubicin (Fig. 6c). The pro-apoptotic influence of p53 on the statin-induced sensitizing effect was confirmed by caspase 3 and PARP cleavage (Fig. 6d). Exposure to exogenous cholesterol...
antagonized these effects on proapoptotic signaling induced by the combination of doxorubicin with simvastatin (Fig. 6c, d). The ability of simvastatin to sensitize cells to doxorubicin-induced apoptosis mirrored the inhibitory drug effects on cell growth (Fig. 6d), further supporting the therapeutic utility of lowering cholesterol levels in the most aggressive EWS cells.

4 Discussion

In this study, we provide evidence that localized EWS patients who underwent conventional multidrug chemotherapy have a more favorable course of disease when tumoral expression of the ABCA6 transporter is high. These clinical data obtained in three independent cohorts of EWS patients are in conformity with a recent report on pancreatic ductal adenocarcinoma [37] and a previous observation in neuroblastoma [38], but in sharp contrast with the general idea that overexpression of ABC transporters is associated with more pronounced malignancy and drug resistance due to their capabilities to export drugs or toxins (through their canonical function of detoxification) [39]. Here, we show that expression of ABCA6 impairs the intracellular levels of cholesterol, which is an important component of cellular membranes reported to regulate membrane fluidity and functionality [40]. Cancer cells accumulate cholesterol, particularly in the cytosolic face of the plasma membrane, where cholesterol offers structural support and strongly affects the stability and function of growth factor receptors, integrins and cell surface glycoproteins. Consequently, the intracellular cholesterol content is involved in the control over major biological processes such as endocytosis, intracellular signaling pathway activation,
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the... 

cell adhesion and motility (for a review, see [41]). Depletion of cholesterol in cancer cells has been reported to reduce tumor cell migration [42] and to increase sensitivity to chemotherapeutic agents [43]. Here, we report that when the ABCA6 transporter is highly expressed, either constitutively or after being forced, cells exhibit low intracellular levels of cholesterol and a reduced capability to migrate, and they are more sensitive to doxorubicin (DXR) exposure. A representative western blot of three is shown. GAPDH was used as a loading control. 

The cholesterol lowering drug simvastatin was found to inhibit IGF1R/AKT/mTOR activation, whereas exogenous cholesterol stimulated upregulation and activation of IGF1R and phosphorylation of AKT/mTOR. This finding is in line with previous exposure alone or in combination with SIM or SIM plus CHOL. 

**Fig. 6** Cholesterol mediates activation of IGF1R/AKT signaling and doxorubicin-induced apoptosis. 

**a**, IGF1R pathway inhibition in PDX-EW#2-C (ABCA6<sup>high</sup>) cells treated with increasing doses of simvastatin (SIM) and after the rescue effect of exogenous cholesterol (CHOL) exposure. A representative western blot of three is shown. GAPDH was used as a loading control. 

**b**, IGF1R pathway induction in PDX-EW#5-C (ABCA6<sup>low</sup>) cells after exogenous cholesterol exposure. A representative western blot of three is shown. 

**c**, AKT/MDM2/p53 proapoptotic pathway activation in PDX-EW#2-C cells after doxorubicin (DXR, 3 h) exposure alone or in combination with SIM or SIM plus CHOL. Data in the graph are the mean ± SEM (n = 3); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. One–way ANOVA versus control (nontreated cells). 

GAPDH was used as a loading control.
studies showing that the activation of IGF1R depends critically on the levels of cholesterol [30–32], which may alter interactions between lipid rafts, including caveolae, and associated tyrosine kinase receptors (for a review see [44]). In particular, it was found that IGF1R phosphorylation is inhibited by cholesterol depletion, while it is restored by the replacement with exogenous cholesterol [32]. Other studies reported an oncogenic and pro-metastatic role of caveolin-1 in EWS [45–47] and how IGF1R signaling is enhanced after caveolin-mediated receptor internalization [48, 49]. Our data, reporting the role of ABCA6 in diminishing intracellular cholesterol, decreasing caveolin-1 expression and inhibiting IGF1R signaling, are consistent with this evidence and support the hypothesis that the ability to form ordered domains is sufficient to support activation of IGF1R signaling and tumor growth. In addition, we provide evidence that through inhibition of IGF1R/AKT signaling, statins also prevent Ser166 phosphorylation of MDM2, leading to an increased p53 response and enhanced pro-apoptotic effects of doxorubicin. Of note, highly malignant EWS cells that express low levels of ABCA6 and have higher levels of intracellular cholesterol are more sensitive to statins. Additionally, pretreatment with simvastatin synergistically increased cell sensitivity to doxorubicin. This finding supports the possible use of statins as adjuvant agents in therapy against EWS. Statins are commonly administered to treat atherosclerotic cardiovascular disease, but they also exert pro-apoptotic, anti-angiogenic and immunomodulatory effects in various tumor cell types (for a review, see [50, 51]) and decrease the development of multidrug resistance.

**Fig. 7** Simplified representation of the relationships between ABCA6, cholesterol (CHOL), and IGF1R signaling in EWS cells in the high malignancy condition (ABCA6low) or the lower aggressive status (ABCA6high). The proposed mechanism is summarized as follows: **a**, when cells express low ABCA6, cellular levels of cholesterol are increased with consequent enrichment in caveolae and IGF1R signaling. Co-localization of IGF1R and caveolin-1 together with enhanced caveolin-dependent IGF1R signaling are well-demonstrated [31, 48, 49]. The sustained activation of IGF1R/AKT triggers both mTOR/S6 signaling, which leads to increased protein synthesis and cell survival, and MDM2. MDM2 phosphorylated at Ser166 favors p53 degradation, which results in an attenuated p53-mediated apoptotic response to DNA-damaging agents. **b**, when cells express high levels of ABCA6, cholesterol efflux is increased, thereby diminishing the total content of cholesterol in the cells and reducing IGF1R/AKT signaling. This prevents the phosphorylation of MDM2 at Ser166, leading to an increased p53 response, while downstream inhibition of mTOR/S6 decreases cell survival. (The images were “Created with BioRender.com)
in vitro (for a review, see [52]). At the clinical level, however, the results related to the use of statins or other cholesterol-lowering drugs are controversial, with some studies suggesting prolonged survival and others reporting no benefit (for a review, see [53]). In this study, we highlight how the expression of ABCA6 may affect the sensitivity to statins, thereby supporting the idea that evaluation of the expression level of these transporters is necessary to identify patients who may benefit from the anticancer effects of statins.

5 Conclusion

Our data indicate that most aggressive EWS are characterized by a lower expression of ABCA6, a condition that facilitates the progression of EWS by keeping cellular cholesterol at high levels. This results in an enrichment of caveolae, sustained activation of IGF1R/AKT signaling, increased function of MDM2 and attenuated p53 responses to DNA-damaging agents. In contrast, high ABCA6 expression was found to be associated with a better patient’s prognosis and, at the cellular level, with improved chemotherapy-induced apoptosis likely due to decreased levels of cholesterol and reduction of pro-survival signaling (Fig. 7). This finding indicates a selective vulnerability of EWS cells and sustains ABCA6 evaluation for a rationale use of statins as adjuvant drugs. Overall, our study highlights the importance of ABCA6 in cancer and provides a mechanistic explanation for its involvement in the regulation of cancer aggressiveness.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13402-022-00713-5.

Acknowledgements The authors wish to thank V. Mularoni, M. Fanelli and E. Simonetti for their technical support and C. Ghinelli for editing the figures of the manuscript. The authors are grateful to Muscolo Skeletal Tumor Biobank—Biobanca dei Tumori Muscoloscheletrici (Biotum), member of the CRB-IOR, which provided us the biological samples. The research here presented received support for the establishment of PDXs model by funds from the European Union (ERANET TRANSCAN-2, TORPEDO ER-2015-2360405 to K. Scotlandi) and HORIZON2020-IM2-ITCC-P4 (grant agreement n°116064 to K. Scotlandi). The laboratory of T. Grünewald was supported by grants from the Barbara und Willfried Mohr foundation, the Gert und Susanna Mayer Foundation, the SMARTCB1 association, the BMBF (SMARTCare), and the German Cancer Aid (DKH-70114111 and -70114278).

Author contributions K.S. and M.P conceived the project; M.P and A.M.G. developed the methodology, performed all the experiments and analyzed the data; C.C., M.C.M., C.M., A.P. and C.B. contributed to the in vitro experiments; P.L.L. contributed to the development of the PDX model; T.G.P.G. and F.C.A. performed the analysis of public available gene expression data; A.L., D.M. and G.M., M.S. contributed to the collection and processing of patient samples and provided clinical data; K.S. and M.P. wrote the manuscript; all the authors revised and approved the manuscript; K.S. supervised the work.

Funding The research leading to these results has received funding from AIRC under IG 2016—ID. 18451—P.I. Scotlandi Katia and under IG2019—ID. 22805—P.I. Scotlandi Katia. The materials presented and views expressed herein are the responsibility of the authors only. The sponsor takes no responsibility for any use of the information presented herein.

Data availability All data generated or analyzed during this study are included in this manuscript and its supplementary files.

Declarations

Ethics approval Ethical committee approval was obtained from the ethics committee of the Rizzoli Institute (21637/2013, 19012/2016, 9323/2016 and 9164/2017) and from the Comitato Etico di Area Vasta Emilia Centro (Codice CE AVEC 505/2019/Sper/IOR). The study was conducted in accordance with the Declaration of Helsinki ethical guidelines, and patient informed consent for research use of biobanking material was obtained.

Consent to participate Not applicable.

Consent for publication Not applicable.

Competing interests The authors have no competing interests to declare that are relevant to the content of this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. A.P. Shah, C.N. Patel, D.K. Sureja, K.P. Sanghavi, A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy. Folia Med (Plovdiv) 60, 39–47 (2018)
2. K. Engle, G. Kumar, Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. Eur J Med Chem 239, 114542 (2022)
3. A. Domenichini, A. Adamska, M. Falasca, ABC transporters as cancer drivers: Potential functions in cancer development. Biochim Biophys Acta Gen Subj 1863, 52–60 (2019)
4. W. Muriithi, L.W. Macharia, C.P. Heming, J.L. Echevarria, A. Nyachioe, P.N. Filho, V.M. Neto, ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med 17, 253–269 (2020)
5. P. Goossens, J. Rodriguez-Vita, A. Eterodt, M. Masse, O. Rastoin, V. Gouirand, T. Ulas, O. Papatontopoulou, M. Van Eck, N. Auphan-Anezin, M. Bebien, C. Verhuy, T.P. Vu Manh, M. Turner, M. Dalod, J.L. Schultz, T. Lawrence, Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression. Cell Metab 29, 1376-1389 e1374 (2019)
6. I. Mantel, B.A. Sadig, J.M. Blander, Spotlight on TAP and its vital role in antigen presentation and cross-presentation. Mol Immunol 142, 105–119 (2022)
7. J.A. Coleman, F. Quazi, R.S. Molday, Mammalian P4-ATPases and ABC transporters and their role in phospholipid transport. Biochim Biophys Acta 1831, 555–574 (2013)
8. M. Pasello, A.M. Giudice, K. Scotlandi, The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer. Semin Cancer Biol 60, 57–71 (2020)
9. W. Szlasi, I. Zrendran, A. Zalesinska, M. Tarek, J. Kulbacka, Lipid composition of the cancer cell membrane. J Bioenerg Biomembr 52, 321–342 (2020)
10. P. Dvorak, M. Pesta, P. Soucek, ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer. Tumour Biol 39, 1014028317699800 (2017)
11. J.P. Ginsberg, P. Goodman, W. Leisenring, K.K. Ness, P.A. Meyers, S.L. Wolden, S.M. Smith, M. Stovall, S. Hammond, L.L. Robison, K.C. Oeffinger, Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 102, 1272–1283 (2010)
12. P.A. Meyers, M.D. Kralio, M. Ladanyi, K.W. Chan, S.L. Sailer, P.S. Dickman, D.L. Baker, J.H. Davis, R.B. Gerbing, A. Grovas, C.E. Herzog, K.L. Lindsley, W. Liu-Mares, J.B. Nachman, L. Sieger, J. Wadman, R.G. Gorlick, High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 19, 2812–2820 (2001)
13. R. Lukesch, A. Tienghi, K.S. Hall, F. Fagioli, P. Picci, E. Barbieri, L. Gandola, M. Eriksson, P. Ruggieri, P. Dutoit, P. Lindholm, A. Prete, G. Bisogno, A. Tamburini, G. Grignani, M.E. Abate, M. Podda, S. Smeland, S. Ferrari, Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloma-like chemotherapy and total-lung irradiation. Ann Oncol 23, 2970–2976 (2012)
14. T. Perri, M. Fogel, S. Mor, G. Horev, I. Meller, D. Loew, J. Isaacs, Y. Kyr, K. Zitterbart, J. Sterba, R. Veselska, Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric Ewing's sarcoma: a possible therapeutic target. Cancer Res 64, 325–334 (2004)
15. K. Scotlandi, M.C. Manara, C.M. Hattinger, S. Benini, S. Perdichizzi, T. Perri, M. Fogel, S. Mor, G. Horev, I. Meller, D. Loven, J. Issaiev, R. Luksch, A. Tienghi, K.S. Hall, F. Fagioli, P. Picci, E. Barbieri, L. Gandola, M. Eriksson, P. Ruggieri, P. Dutoit, P. Lindholm, A. Prete, G. Bisogno, A. Tamburini, G. Grignani, M.E. Abate, M. Podda, S. Smeland, S. Ferrari, Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloma-like chemotherapy and total-lung irradiation. Ann Oncol 23, 2970–2976 (2012)
16. E. Roundhill, S. Burchill, Membrane expression of MRP-1, with adjuvant or neoadjuvant chemotherapy between 1972 and 1990. Ann Oncol 14, 555–574 (2003)
17. I. Zambo, M. Hermanova, D. Zapletalova, J. Skoda, L. Zanella, E. Barbieri, A. Picci, T. Bohling, G. Bacci, S. Ferrari, L. Sangiorgi, M. Mercuri, P. Ruggieri, M. Manfrini, A. Ferraro, R. Casadei, M.S. Benassi, A.F. Mancini, P. Rosito, A. Cazzola, E. Barbieri, A. Tienghi, A. Brach del Prever, A. Comandone, P. Bacchini, F. Bertoni, Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol 15, 1553–1559 (1997)
18. P. Nanni, L. Landuzzi, M.C. Manara, A. Righi, G. Nicoletti, C. Cristalli, M. Pasello, A. Parra, M. Carrabotta, M. Ferracin, A. Palladini, M.L. Ianzano, V. Giusti, F. Ruzzi, M. Magnani, D.M. Donati, P. Picci, P.L. Lollini, K. Scotlandi, Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Sci Rep 9, 12174 (2019)
19. M.J. Bradburn, T.G. Clark, S.B. Love, D.G. Altman, Survival analysis Part III: multivariate data analysis – choosing a model and assessing its adequacy and fit. Br J Cancer 89, 605–611 (2003)
20. T.C. Chou, R.J. Motzer, Y. Tong, G.J. Bosl, Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86, 1517–1524 (1994)
21. J.Q. Wang, Z.X. Wu, Y. Yang, Q.X. Teng, Y.D. Li, Z.N. Lei, K.A. Jani, N. Kaushal, Z.S. Chen, ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. J Evid Based Med 14, 232–256 (2021)
22. F.R. Maxfield, D. Wustner, Analysis of cholesterol trafficking with fluorescent probes. Methods Cell Biol 108, 367–393 (2012)
23. W.W. Wong, J. Dimitroulakos, M.D. Minden, L.Z. Penn, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508–519 (2002)
24. H.J. Jiang, E.M. Hong, S.W. Park, H.W. Byun, D.H. Koh, M.H. Choi, S.H. Kae, J. Lee, Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation. Oncol Lett 12, 250–256 (2016)
25. Y. Sekine, Y. Furuya, M. Nishii, H. Koike, H. Matsu, K. Suzuki, Simvastatin inhibits the proliferation of human prostate cancer cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 372, 356–361 (2008)
26. C. Mancarella, K. Scotlandi, IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy. J Mol Endocrinol 61, T45–T60 (2018)
27. L.C. Matthews, M.J. Taggart, M. Westwood, Effect of cholesterol depletion on mitogenesis and survival: the role of caveolar and noncaveolar domains in insulin-like growth factor-mediated cellular function. Endocrinology 146, 5463–5473 (2005)
28. X. Lu, F. Kambe, X. Cao, M. Yamauchi, H. Seo, Insulin-like growth factor-I activation of Akt survival cascade in neuronal cells requires the presence of its cognate receptor in caveolae. Exp Cell Res 314, 342–351 (2008)
29. R.J. DelleBovi, J. Kim, P. Suresh, E. London, W.T. Miller, Sterol structure dependence of insulin receptor and insulin-like growth factor 1 receptor activation. Biochim Biophys Acta Biomembr 1861, 819–826 (2019)
30. D. Hailstones, L.S. Slee, R.G. Parton, K.C. Stanley, Regulation of caveolin and caveole by cholesterol in MDCK cells. J Lipid Res 39, 369–379 (1998)
31. K. Scotlandi, S. Benini, M. Sarti, M. Serra, P.L. Lollini, D. Maurici, P. Picci, M.C. Manara, N. Baldini, Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 56, 4570–4574 (1996)
32. K. Scotlandi, S. Avnet, S. Benini, M.C. Manara, M. Serra, V. Cerisano, S. Perdichizzi, P.L. Lollini, C. De Giovanni, L. Landuzzi, P. Picci, Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing’s sarcoma cells. Int J Cancer 101, 11–16 (2002)
33. B.P. Zhou, Y. Liao, W. Xia, Y. Zou, B. Spohn, M.C. Hung, HER-2/ neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3, 973–982 (2001)

Springer
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the...